Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Koninklijke Philips NV (PHG) Price & Performance

Abeona Therapeutics IncTrade
Koninklijke Philips NVTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Koninklijke Philips NV — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Koninklijke Philips NV trades at $26.99 (market cap $26.33B). The key difference: Koninklijke Philips NV is far larger — about 62.1× Abeona Therapeutics Inc's market cap, and Koninklijke Philips NV pays a 3.76% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOPHG
Market Cap
$424.33M$26.33B
Sector
HealthHealth
52-Week High
$7.45$32.91
52-Week Low
$4.17$25.02
Enterprise Value
$279.23M$32.89B
Dividend Yield
3.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.

Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.

Koninklijke Philips NV

PHG trades at $26.73, up 1.52% today, with a bullish technical signal and recent earnings beats in Q4 2025, Q1 2026, and Q2 2026. The company reported $17.83B revenue and $895M net income for 2025, with a P/E of 20.29 and net margin of 6.31%. Recent news highlights Exor increasing its stake and FDA clearances for new health tech products, supporting positive sentiment.

Outlook is cautiously optimistic with strong profitability and institutional interest, but risks include order intake volatility and debt levels. Analysts show 40.9% buy ratings, indicating potential upside if execution continues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Koninklijke Philips NV

Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.

Read more on PHG